Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Madhuri Are

Interventional Pain Medicine Omaha, NE Medical Doctor

NPI 1114018025 CMS profile 323137

984030 Nebraska Medical Center, Omaha, NE 68198

Open in the dashboard

General payments

$904

18 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Madhuri Are of Omaha, NE is reported in the CMS Open Payments database as having received $904 across 18 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 23rd percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $275 10
2024 General $459 4
2023 General $103 3
2022 General $67 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Madhuri Are
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Madhuri Are were reported at $275. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Madhuri Are Interventional Pain Medicine median Middle half National median
2019 $0 $684 $216–$2,079 $163
2020 $0 $382 $122–$1,109 $114
2021 $0 $552 $167–$1,554 $132
2022 $67 $605 $187–$1,924 $149
2023 $103 $671 $195–$1,915 $160
2024 $459 $684 $206–$1,837 $164
2025 $275 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Saluda Medical Americas, Inc. $279 2 payments
  2. Abbott Laboratories $170 4 payments
  3. Averitas Pharma Inc. $167 5 payments
  4. SPR Therapeutics, Inc $108 3 payments
  5. Boston Scientific Corporation $88 1 payment
  6. Nalu Medical, Inc. $75 2 payments
  7. Medtronic, Inc. $17 1 payment

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $904 18 payments
Products named General payments · program years 2022–2025
  1. Evoke $279 2 payments
  2. Qutenza $167 5 payments
  3. SPRINT PNS System $108 3 payments
  4. PROCLAIM Neuromodulation $84 2 payments
  5. Nalu Neurostimulation System $75 2 payments
  6. PROCLAIM Neuromodulation $45 1 payment
  7. PROCLAIM Neuromodulation $40 1 payment
  8. INCEPTIV $17 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

317

Median for Pain Management: 951

Drug cost

$24,500

Median for Pain Management: $26,034

Branded share of claims

8.8%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Emgality Pen Galcanezumab-Gnlm Brand 28 $20,077
Gabapentin Generic 97 $1,427
Duloxetine Hcl Generic 74 $1,149
Naltrexone Hcl Generic 23 $689
Ropinirole Hcl Generic 23 $452
Pregabalin Generic 24 $414
Meloxicam Generic 24 $129
Methocarbamol Generic 12 $121
Cyclobenzaprine Hcl Generic 12 $42

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 50 billing codes

Paid by Medicare

$43,402

Medicare's payments for the services billed

Medicare patients

193

Average age 71

Services billed

578

111 women, 82 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 74%
Chronic kidney disease 34%
Depression 34%
Diabetes 26%
Ischemic heart disease 26%
COPD 23%
Cancer 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

18 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Nebraska

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record